Global Cervical Dystonia Therapeutics Market 2019-2023: Expected Approval of Late-Stage Pipeline Molecules to be a Driving Influence - ResearchAndMarkets.com

The "Global Cervical Dystonia Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The cervical dystonia therapeutics market will register a CAGR of almost 5% by 2023.

With the rise in reimbursement programs for botulinum neurotoxin injections, there is a growing demand for treatment of cervical dystonia. Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia. These reimbursement programs help patients with or without medical insurance to achieve appropriate reimbursement for their treatment with botulinum toxins.

For instance, Allergan, the manufacturer of BOTOX, sponsors a comprehensive reimbursement program called as BOTOX Reimbursement Solutions Program. This program includes a BOTOX Hotline and BOTOX Patient Assistance Program to assist patients who are receiving BOTOX injection treatment.

Market Overview

Expected approval of late-stage pipeline molecules

The global cervical dystonia therapeutics industry is forecasted to witness a steady growth owing to the expected approval of late-stage molecules in the pipeline for the treatment of cervical dystonia. The cervical dystonia therapeutics market is also expected to benefit from the growing number of molecules being launched for the treatment of the disease.

Availability of alternate therapies

For the treatment of cervical dystonia, botulinum toxins and other therapeutics are used. However, the low rate of success and temporary cure of these therapeutics leads people towards alternative therapies such as DBS surgery, which is a major challenge for the growth of the market.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Allergan and Eisai, the competitive environment is quite intense. Factors such as the rising number of reimbursement programs for botulinum neurotoxin injections and the anticipated approval of late-stage pipeline molecules, will provide considerable growth opportunities to cervical dystonia therapeutic vendors. Allergan, Eisai, Ipsen Pharma, Merz Pharma, and US WorldMeds are some of the major companies covered in this report.

Report Summary:

One trend affecting this market is the reimbursement for botulinum neurotoxin injections. Several reimbursement programs are available to help people access the high-cost botulinum neurotoxin therapy for the treatment of cervical dystonia. These reimbursement programs help patients with or without medical insurance to achieve appropriate reimbursement for their treatment with botulinum toxins.

According to the report, one driver influencing this market is the expected approval of late-stage pipeline molecules. As the market is witnessing an acute lack of more approved cervical dystonia therapeutics, these late-stage pipelines molecules have the potential to tap the unmet demand from the patient pool for treatment of cervical dystonia.

Further, the report states that one challenge affecting this market is the product withdrawals. The global sepsis therapeutics market has an acute lack of approved therapies, resulting in huge unmet needs among sepsis patients and hampering the growth of the market.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Botulinum toxins - Market size and forecast 2018-2023
• Other therapeutics - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Allergan
• Eisai
• Ipsen Pharma
• Merz Pharma
• US WorldMeds

PART 14: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/hz42vh/global_cervical?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181121005221/en/